{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-25-000493","form_type":"8-K","ticker":"TEVA","cik":"0000818686","company_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","filed_at":"2025-01-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:06.431142+00:00","generated_at":"2026-05-27T07:42:31.126769+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Teva FY2024 revenue $16.5B, GAAP EPS loss $1.45; non-GAAP EPS $2.49; sees 2025 rev $16.8-17.4B","bullets":["FY2024 revenues $16.5B, +4% USD (+6% local currency); GAAP net loss $1.639B ($1.45/share) vs $559M loss in FY2023.","Non-GAAP diluted EPS $2.49, down from $2.56; adjusted EBITDA $4.78B.","Key product revenues: AUSTEDO >$1.6B, AJOVY $507M (+18% local), UZEDY $117M.","Generics grew 15% in U.S., 6% in Europe, 15% in International Markets (local currency).","FY2025 outlook: revenue $16.8-$17.4B, non-GAAP EPS $2.35-$2.65, free cash flow $1.6-$1.9B."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-25-000493","json":"https://secwatch.observer/filing/0001171843-25-000493.json","markdown":"https://secwatch.observer/filing/0001171843-25-000493.md","text":"https://secwatch.observer/filing/0001171843-25-000493.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/818686/000117184325000493/0001171843-25-000493-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/818686/000117184325000493/f8k_012925.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T07:42:31.126769+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}